Rare diseases
Investigational molecules
Locations
Recruiting trials first
9 clinical trials in this condition
Belgium
Italy
Spain
The NetherlandsIn short
Treating dilated cardiomyopathy involves a combination of approaches aimed at managing symptoms, slowing disease progression, and improving quality of life for patients living with this heart muscle condition.
When doctors diagnose dilated cardiomyopathy, they focus on several important treatment goals. The main aim is to help the heart pump blood more effectively, even though the heart muscle has become stretched and weakened. Treatment seeks to reduce symptoms like shortness of breath, fatigue, and swelling in the legs or abdomen. Doctors also work to prevent the condition from getting worse and to lower the risk of serious complications such as heart failure, which happens when the heart cannot keep up with the body's needs for blood and oxygen.
Treatment plans vary greatly from one patient to another. What works well for one person may need adjustment for someone else. The approach depends on how severe the condition is, what caused it in the first place, whether the patient has other health problems, and how the patient responds to initial treatments. Some people may not notice symptoms in the early stages, while others may experience more obvious signs that require more intensive care.
There are standard treatments that medical societies and guidelines recommend based on years of research. These include medications that have proven effective in helping the heart work better and devices that can support heart function. Beyond these established treatments, researchers are constantly exploring new therapies in clinical trials. These studies test innovative medicines and approaches that might become standard treatments in the future. Patients may have the option to participate in these trials, depending on their specific situation and location.
The foundation of treating dilated cardiomyopathy involves medications that have been tested extensively and shown to help patients live longer and feel better. Doctors typically prescribe a combination of drugs, each working in a different way to support heart function.
Angiotensin-converting enzyme inhibitors, commonly called ACE inhibitors, are among the first medications doctors prescribe. These drugs make it easier for blood to flow through the body by relaxing blood vessels. When blood vessels are more relaxed, the heart doesn't have to work as hard to pump blood. ACE inhibitors also help prevent the heart muscle from getting even more damaged over time. Common examples include enalapril and lisinopril. Patients may experience side effects such as a dry cough, dizziness when standing up, or changes in kidney function, which doctors monitor through regular blood tests.
When patients cannot tolerate ACE inhibitors, doctors may prescribe angiotensin receptor blockers (ARBs). These medications work similarly to ACE inhibitors but through a slightly different mechanism. They block the action of a hormone that causes blood vessels to narrow. ARBs tend to cause fewer side effects like coughing compared to ACE inhibitors, making them a good alternative.
A newer class of medication called angiotensin receptor-neprilysin inhibitors (ARNI) combines an ARB with another drug that prevents the breakdown of helpful substances in the body. The combination drug sacubitril/valsartan has shown superior results compared to ACE inhibitors alone in patients with reduced heart pumping ability. In clinical trials, patients taking ARNI had fewer hospital admissions for heart failure and better survival rates. This medication requires careful monitoring and is typically started at a low dose and gradually increased.
Beta-blockers are another essential medication class for dilated cardiomyopathy. These drugs slow down the heart rate and reduce the force of each heartbeat, which might seem counterintuitive when the heart is already weak. However, by slowing the heart down, beta-blockers actually help the heart fill with blood more completely between beats and reduce the strain on the heart muscle. Over time, this can lead to improvement in how well the heart pumps. Common beta-blockers include carvedilol, metoprolol, and bisoprolol. Side effects may include fatigue, dizziness, and sometimes worsening symptoms when first started, which is why doctors begin with very low doses and increase gradually over weeks or months.
Aldosterone antagonists, also called mineralocorticoid receptor antagonists, help remove excess fluid from the body and protect the heart from further damage. These medications, such as spironolactone and eplerenone, block a hormone that can cause the heart to remodel in harmful ways. They are particularly helpful in patients with more advanced heart failure. Doctors monitor blood potassium levels carefully in patients taking these drugs because they can cause potassium to build up to dangerous levels.
Diuretics, sometimes called water pills, help the body get rid of extra fluid that builds up when the heart isn't pumping effectively. This reduces swelling in the legs, ankles, and abdomen, and makes breathing easier when fluid accumulates in the lungs. Common diuretics include furosemide and bumetanide. While they don't help the heart pump better or extend life, they are important for managing symptoms and helping patients feel more comfortable. Side effects can include frequent urination, dehydration, and imbalances in body salts like potassium and sodium.
Some patients may also receive cardiac glycosides like digoxin. This older medication can help the heart contract more strongly and control heart rate, especially in patients who have irregular heartbeats called atrial fibrillation. However, digoxin must be dosed carefully because too much can cause serious side effects.
For certain patients, doctors may prescribe ivabradine, a medication that specifically slows the heart rate without affecting blood pressure or the force of heart contractions. This can be helpful for patients who still have a fast heart rate despite taking beta-blockers, or who cannot tolerate higher doses of beta-blockers.
Another important medication class is sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors). Originally developed to treat diabetes, these drugs have shown benefits for heart failure patients even without diabetes. They help the kidneys remove excess sugar and sodium, reducing fluid buildup and providing some protection to the heart. Side effects may include increased urination and, rarely, infections.
The duration of treatment varies. Many patients need to take these medications for the rest of their lives to keep their condition controlled. Some patients experience significant improvement and may be able to reduce medications under careful doctor supervision, but most will require ongoing treatment. Regular follow-up appointments are essential to monitor how well medications are working and to adjust doses as needed.
Beyond medications, patients may need medical devices implanted to help their heart function better or prevent dangerous complications. An implantable cardioverter-defibrillator (ICD) is a small device placed under the skin near the collarbone with wires extending to the heart. It continuously monitors heart rhythm and can deliver an electrical shock if it detects a life-threatening irregular heartbeat. This can prevent sudden cardiac death, which is a risk for some patients with dilated cardiomyopathy.
For patients whose heart chambers don't contract in a coordinated way, cardiac resynchronization therapy (CRT) may help. This is a special type of pacemaker that sends electrical signals to both sides of the heart simultaneously, helping the chambers pump together more effectively. CRT can improve symptoms and quality of life in selected patients who have a specific type of electrical problem in their heart along with reduced pumping function.
When medical treatments and devices are not enough, some patients may need more advanced options. A left ventricular assist device (LVAD) is a mechanical pump implanted in the chest that helps the weakened heart pump blood. LVADs can be used as a bridge to keep patients alive while waiting for a heart transplant, or as a long-term solution for patients who are not candidates for transplant. Finally, heart transplantation may be an option for patients with severe, progressive disease that doesn't respond to other treatments, though this requires careful evaluation and depends on donor availability.
While standard treatments have greatly improved outcomes for patients with dilated cardiomyopathy, researchers continue to search for even better therapies through clinical trials. These studies test new medications, innovative devices, and novel approaches that might offer additional benefits or work better for specific patient groups.
One exciting area of research involves stem cell therapy. Scientists are exploring whether stem cells can help repair damaged heart muscle or encourage the body to grow new, healthy heart cells. Different types of stem cells are being studied, including bone marrow-derived hematopoietic stem cells, which are cells that normally help produce blood cells but might also support heart muscle healing. Another type is mesenchymal stem cells, which can develop into various tissue types and may help reduce inflammation and scarring in the heart. Researchers are also investigating adipose-derived stem cells, which come from fat tissue and might differentiate into heart muscle cells.
These stem cell studies typically occur in Phase I or Phase II trials. Phase I trials focus primarily on safety, testing whether the treatment causes harmful effects in small groups of patients. Phase II trials expand to larger groups and begin to assess whether the treatment actually improves heart function or symptoms. Early results from some studies have shown that stem cell therapy might help improve the heart's pumping ability and reduce the amount of scar tissue in the heart muscle. However, researchers note that more work is needed to determine which type of stem cells works best, what dose should be used, and how often treatments should be given.
Another investigational approach involves gene therapy, which aims to correct or compensate for genetic problems that cause dilated cardiomyopathy. Since genetic mutations account for more than half of dilated cardiomyopathy cases in some studies, fixing the underlying genetic problem could potentially stop or even reverse the disease. Researchers are developing ways to deliver healthy genes or turn off faulty genes in heart muscle cells. This work is still in early stages, but it represents a potentially transformative approach for patients with genetic forms of the disease.
Clinical trials studying new medications focus on different targets in the body. Some experimental drugs aim to reduce inflammation in the heart muscle, while others try to improve how the heart uses energy or prevent harmful remodeling of the heart structure. Researchers may test molecules with code names like JK07 or ARRY-371797 in early-phase studies. These investigational drugs work through novel mechanisms that differ from current standard treatments, potentially offering benefits for patients who don't respond well to existing therapies.
Many clinical trials take place in multiple locations, including major medical centers in the United States, Europe, and increasingly in other parts of the world. Eligibility for these trials depends on many factors, including the severity of heart disease, the specific cause of cardiomyopathy, whether patients have tried standard treatments, and their overall health status. Patients interested in clinical trials should discuss options with their cardiologist, who can help determine if any appropriate studies are available and whether participation might be beneficial.
It's important to understand that therapies being tested in clinical trials are not yet proven to work. Some will turn out to be effective and eventually become standard treatments, while others may not show enough benefit or may cause unacceptable side effects. Participation in clinical trials helps advance medical knowledge and may give patients access to potentially helpful new treatments, but it also involves uncertainty and requires careful consideration and informed consent.
This guide is here to help you understand the condition. It does not replace a conversation with your doctor, who knows your situation best.
Patient organisations offering help, community and advocacy
Tell us about your condition – we search every trial in Europe and connect you with the right site.
